MAGE-3.A1 Peptide Vaccine

Known as: HLA-A1-Restricted MAGE-3 Peptide Vaccine, MAGE-3.A1 
A synthetic peptide cancer vaccine consisting of human leukocyte antigen HLA-A1-restricted peptide derived from human melanoma antigen 3 (MAGE-3… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2014
012319982014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
We previously characterized the CTL response of a melanoma patient who experienced tumor regression following vaccination with an… (More)
Is this relevant?
2008
2008
Tumor regressions have been observed in a small proportion of melanoma patients vaccinated with a MAGE-A3 peptide presented by… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2006
2006
Gene MAGE-A3 encodes tumor-specific antigenic peptides recognized by T cells on many tumors. MAGE-A3 peptides presented by HLA… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Melanoma patients have high frequencies of T cells directed against antigens of their tumor. The frequency of these antitumor T… (More)
  • figure 1
  • figure 2
  • table I
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The cancer-germline gene MAGE-3 codes for tumor-specific antigens recognized on many tumors by T lymphocytes. A MAGE-3 antigen… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2003
2003
Vaccination with mature, monocyte-derived dendritic cells (DC) pulsed with the MAGE-3(168-176) peptide, which is presented by HLA… (More)
  • figure 1
  • figure 2
Is this relevant?
2003
2003
We have analyzed the T cell responses of HLA-A1 metastatic melanoma patients with detectable disease, following vaccination with… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Cell surface expression of HLA class I/peptide complexes on tumor cells is a key step in the generation of T-cell-based immune… (More)
Is this relevant?
2001
Highly Cited
1999
Highly Cited
1999
Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide… (More)
Is this relevant?